New research from Pfizer found a drop-off in protection after six months, though the vaccines remained highly effective against severe illness.
“This data is all really encouraging and exactly what you’d expect,” he said.
The new research looked at follow-up data gathered through March 13 on the more than 44,000 people who participated in Pfizer’s phase 3 clinical trial last year. Individuals either received two doses of the vaccine or two doses of a placebo three weeks apart. Because the study only looked at data through mid-March, it remains unclear how the shots fare against the delta variant, which became the mostThe findings come as experts continue to consider whether or not booster shots will be necessary.
Offit stressed that because the vaccine remains very effective at preventing severe disease and hospitalizations, it’s too early to definitively say that booster shots will be required. Dr. Bob Wachter, chairman of the department of medicine at University of California, San Francisco, agreed with Offit that the new data do not suggest it’s time to rush out and get a booster shot yet.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Citing New Data, Pfizer Outlines Case for Booster ShotsPfizer offered new evidence on Wednesday in support of booster shots of its potent vaccine, reporting that the vaccine’s power wanes slightly over time but may be improved with a third dose. The new data, which have not yet been peer-reviewed nor published in a scientific journal, nonetheless confirm that the two-dose vaccine offers potent protection against the coronavirus. Whether booster shots will be widely needed is far from settled, the subject of heated debate among scientists. So far, fe
Consulte Mais informação »
Israel Begins Pfizer Covid-19 Vaccine for At-Risk Children Under 12 as Delta Cases SurgeThe country has authorized the use of Pfizer’s Covid-19 vaccine for vulnerable children between five and 11 years old, as cases of the highly contagious Delta variant rise sharply.
Consulte Mais informação »
Pfizer And Moderna To Expand Studies Of Vaccines In 5- To 11-Year-OldsAt the request of the FDA, the vaccine makers are expanding their trials with young children, seeking to better detect very rare heart issues.
Consulte Mais informação »
Pfizer And Moderna To Expand Studies Of Vaccines In 5- To 11-Year-OldsAt the request of the FDA, the vaccine makers are expanding their trials with young children, seeking to better detect very rare heart issues.
Consulte Mais informação »
Pfizer data suggest third dose of Covid-19 vaccine 'strongly' boosts protection against Delta variantA third dose of the Pfizer/BioNTech Covid-19 vaccine can 'strongly' boost protection against the Delta variant -- beyond the protection afforded by the standard two doses, suggests new data released by Pfizer on Wednesday.
Consulte Mais informação »
Pfizer Raises Full-Year Outlook on Covid-19 Vaccine SalesThe pharmaceutical company’s Covid-19 vaccine co-developed with BioNTech contributed $7.8 billion to Pfizer’s total sales of $18.98 billion in the latest quarter.
Consulte Mais informação »